Next-Generation KRAS G12C Inhibitor Divarasib Shows Improved Survival in Non–Small Cell Lung Cancer

Results from the phase 3 Krascendo 1 study indicate that divarasib, an oral next-generation KRAS G12C inhibitor, significantly improved progression-free survival and overall survival compared to approved first-generation KRAS G12C inhibitors (sotorasib and adagrasib) in patients with previously treated KRAS G12C-mutated advanced or metastatic non–small cell lung cancer (NSCLC).

Context

KRAS mutations are common in various cancers, with the G12C variant being particularly prevalent in NSCLC. First-generation KRAS G12C inhibitors, such as sotorasib and adagrasib, have been used in treatment but have limitations in efficacy. The Krascendo 1 study aimed to evaluate the effectiveness of divarasib, a next-generation inhibitor, in improving patient outcomes compared to existing therapies.

Why it matters

The development of divarasib represents a significant advancement in the treatment of non-small cell lung cancer (NSCLC), particularly for patients with KRAS G12C mutations. Improved survival rates can enhance the quality of life and treatment outcomes for this patient population. As lung cancer remains a leading cause of cancer-related deaths, effective therapies are crucial for addressing this public health challenge.

Implications

If divarasib is approved, it could shift treatment protocols for advanced NSCLC, potentially leading to better patient outcomes. Healthcare providers may need to adapt to new prescribing guidelines and patient management strategies. Patients with KRAS G12C mutations may experience improved survival rates, which could influence treatment decisions and healthcare costs.

What to watch

The results of the Krascendo 1 study could lead to divarasib receiving regulatory approval for clinical use, expanding treatment options for patients with KRAS G12C-mutated NSCLC. Ongoing monitoring of patient responses and long-term survival rates will be critical in assessing the drug's impact. Additionally, the pharmaceutical industry may increase research into other next-generation treatments based on these findings.